首页> 外文OA文献 >Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate

【2h】

Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate

机译：红骨髓吸收剂量为177Lu-lilotomab磷酸丁烷治疗的非霍奇金淋巴瘤患者，一种新型抗CD37抗体 - 放射性核素缀合物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Johan Blakkisrud; Ayca Løndalen; Jostein Dahle; Simon Turner; Harald Holte; Arne Kolstad; Caroline Stokke;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate [J] . Johan Blakkisrud, Ayca L??ndalen, Jostein Dahle, The Journal of Nuclear Medicine . 2017,第1期

机译：新型抗CD37抗体-放射性核素结合物177Lu-Lilotomab Satetraxetan治疗的非霍奇金淋巴瘤患者的红色骨髓吸收剂量
2. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan [J] . Johan Blakkisrud, Ayca L??ndalen, Anne C.T. Martinsen, The Journal of Nuclear Medicine . 2017,第1期

机译：抗CD37抗体放射性核素结合177Lu-Lilotomab沙丁西坦治疗的非霍奇金淋巴瘤患者的肿瘤吸收剂量
3. Pre-dosing with lilotomab prior to therapy with 177 Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients [J] . Caroline Stokke, Johan Blakkisrud, Ayca L?ndalen, European Journal of Nuclear Medicine and Molecular Imaging . 2018,第7期

机译：用Lilotomab进行含有177 Lu-Lilotomab磷酸盐在治疗前的预用显着提高了非霍奇金淋巴瘤患者的肿瘤与红骨的比例
4. Measurements with MOSFET of the radiation dose delivered to patients treated with modulated beams [C] . European Conference on Radiation and Its Effects on Components and Systems . 2005

机译：用调制光束处理的辐射剂量的MOSFET测量
5. Estimation of G-CSF effectiveness in reducing neutropenia hospitalization among Non-Hodgkin's Lymphoma (NHL) patients treated with anthracycline-based chemotherapy. [D] . Pan, Xiaoyun. 2010

机译：估计G-CSF在以蒽环类为基础的化学疗法治疗的非霍奇金淋巴瘤（NHL）患者中减少中性粒细胞减少症住院的有效性。
6. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients [O] . Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, -1

机译：在非霍奇金淋巴瘤患者中在用177Lu-lilotomab沙曲西坦治疗之前预先给予lilotomab可以显着增加肿瘤与红骨髓吸收剂量的比率
7. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan [O] . Johan Blakkisrud, Ayca Løndalen, Anne C.T. Martinsen, 2016

机译：用于非霍奇金淋巴瘤患者的肿瘤吸收剂量，用抗CD37抗体放射核素缀合物177LU-LILOTOMAB Satetraxetan

Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate

著录项

引文网络

相似文献

相关主题

期刊订阅